Pharm
Benralizumab
search
Benralizumab
, Fasenra
See Also
Asthma Monoclonal Antibody
Severe Persistent Asthma
Asthma Management
Omalizumab
Mepolizumab
Reslizumab
Dupilumab
Indications
See
Asthma Monoclonal Antibody
Third-line agents for refractory,
Type 2 Asthma
(
Allergic Asthma
or
Eosinophilic Asthma
, represents 50% of
Asthma
)
Despite long acting
Bronchodilator
and
Inhaled Corticosteroid
s
One of the following findings present
Blood
Eosinophil
s >150/uL
Sputum
Eosinophil
s >2%
Ferrous
Nitrous Oxide
>20 parts per billion
Maintenance oral
Corticosteroid
s required
Precautions
Treat
Helminth
infections prior to starting therapy
Dosing
May be used in age >=12 years old U.S. (>=18 years old Canada)
Dose 30 mg SQ every 4 weeks for 3 doses, then every 8 weeks
Subcutaneous (SQ) injection sites include upper arm,
Abdomen
and thigh
Mechanism
Interleukin-5 Antagonist
(alpha-directed cytolytic
Monoclonal Antibody
, IgG1 Kappa)
Similar to
Mepolizumab
Binds
Interleukin
5 receptor on
Eosinophil
s and
Basophil
s (
Asthma
-related inflammatory cells)
Marks these inflammatory cells for
Natural Killer Cell
mediated death
Safety
Unknown safety in pregnancy
Unknown safety in
Lactation
Adverse Effects
See
Asthma Monoclonal Antibody
Fever
Headache
(8%)
Pharyngitis
(5%)
Resources
Biologic Therapy in
Asthma
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405559/
Benralizumab (DailyMed)
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da6aca1a-19ed-44a4-abb7-696c7d58b784
References
(2022) Comparison of
Asthma
Medications, Presc Lett, #381217
(2020) Drugs for
Asthma
, Med Lett Drug Ther 62: 193-200
(2018) Biologics for
Asthma
, Presc Lett
Narasimhan (2021) Am Fam Physician 103(5): 286-90 [PubMed]
Raymond (2023) Am Fam Physician 107(4): 358-68 [PubMed]
Ortega (2014) N Engl J Med 371(13): 1198-207 [PubMed]
Type your search phrase here